Treatment of systemic lupus erythematosus with LJP 394

Journal of Rheumatology

Volumn 28, Issue 2, 2001, Pages 257-265

  Furie, R A ^a   Cash, J M ^a   Cronin, M E ^a   Katz, R S ^a   Weisman, M H ^a   Aranow, C ^a   Liebling, M R ^a   Hudson, N P ^a   Berner, C M ^a   Coutts, S ^a   De Haan, H A ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

Clinical trial; LJP 394; Systemic lupus erythematosus; Tolerance; Treatment

Indexed keywords

ABETIMUS; DNA ANTIBODY; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOMODULATION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHLEBITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES; DISABILITY EVALUATION; DNA; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OLIGONUCLEOTIDES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 0035118621     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus; association of high avidity antinative DNA antibody with glomerulonephritis
2. Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus
3. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakisoligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis
4. Pharmacologic intervention in antibody mediated disease
5. Reduction in circulating dsDNA antibody titer after administration of LJP 394
6. The 1982 revised criteria for the classification of systemic lupus erythematosus
7. Validity and reliability of lupus activity measures in the routine clinic setting
8. The MOS Short-Form general health survey; reliability and validity in a patient population
9. Antibodies to DNA
10. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus glomerulonephritis: Association of high avidity antinative DNA antibody with glomerulonephritis
11. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus
12. Anti-DNA antibodies and lupus nephritis; the complexity of crossreactivity
13. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans
14. Possible pathogenic role of cationic anti-DNA autoantibodies in the development of nephritis in patients with systemic lupus erythematosus
15. Immunoadsorbent plasma perfusion in patients with systemic lupus erythematosus
16. High-affinity anti-DNA antibody parallels clinical course of immunoadsorption therapy for systemic lupus erythematosus
17. Intravenous immune globulin therapy of lupus nephritis: Use of pathogenic anti-DNA-reactive IgG
18. Updated phase I clinical results with an idiotypic vaccine (3El0) for systemic lupus erythematosus
19. Recombinant human DNase I (rhDNase) in patients with lupus nephritis